Mounjaro (Tirzepatide) Injection


Mounjaro will be available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) and will come in an auto-injector pen with a pre-attached, hidden needle that patients do not need to handle or see. The medication is self-administered one time each week and can be injected under the skin of the stomach, thigh, or upper arm.



Mounjaro (Tirzepatide) Injection

Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. It is the newest injectable medication for the treatment of type II diabetes and obesity.

The U.S. Food and Drug Administration (FDA) has approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes (T2D), as an addition to diet and exercise. The drug, manufactured by Eli Lilly, improved blood sugar more effectively than the other diabetes therapies that were included in the clinical studies that were the basis for its approval, according to the FDA statement, released on May 13.

It’s estimated that more than 37 million people in the United States have type 2 diabetes, according to the Centers for Disease Control and Prevention (CDC). People with T2D are twice as likely to have heart disease or stroke compared to someone without diabetes, and at a younger age, per the agency.